Unlocking intracellular targets with highly specific TCR-like antibodies
Specificity is key to developing safe TCR or TCR-like antibody therapeutics. YUMAB’S novel CHO-display library presents the natural human pHLA repertoire on the cell surface, thereby enabling thorough counter-selections and screenings to identify TCRs or TCR-like antibodies with minimal off-target binding at early stages of drug discovery. This case study explains how our new TCRm […]
Unlocking complex targets with paired antibody libraries
While conventional combinatorial libraries remain highly effective for a wide range of targets and offer significant diversity, paired antibody libraries enable the discovery of more functional antibodies with higher affinities, especially for complex or structurally demanding targets such as glycans. In this case study, we have identified over 1,000 glycan-specific clones using paired libraries compared […]
03.11. – 05.11.2025 | BIO Europe
Vienna, Austria
YUMAB and InSCREENeX get funding for innovative Mammalian Display screening
YUMAB and InSCREENeX are developing an innovative „Mammalian Display“ screening platform to accelerate antibody development. Braunschweig, January 29th, 2025 – YUMAB GmbH, a German biotechnology company specializing in contract research for therapeutic antibodies, announces its collaboration with InSCREENeX GmbH to establish a novel technology for antibody development. As part of the funded project „Mammalian Display,“ […]
Engineering of rare, naturally occurring non-developable antibodies into powerful therapeutics
Rare antibodies with unusual structures and ultra-long CDRs have the potential to bind to difficult-to-access epitopes (e.g., GPCRs, ion channels), and thus offer a unique mode of action. But since they are considered non-developable, they are often excluded from rationally designed antibody libraries or neglected in developability-driven AI selections. This application note demonstrates how tailored […]
Novel NKG2D-targeting bispecific antibodies improve B cell lymphoma killing
In collaboration with the universities of Kiel, Munich, and Braunschweig, a novel bispecific antibody CD20xNKG2D was developed to enhance lymphocyte recruitment and mediate killing of B cell lymphoma cells. Read more
PROxAbs: Next generation PROTACs to access difficult targets
In collaboration with YUMAB, scientists from Merck KGaA have developed a PROTAC-Antibody shuttle (PROxAb) to improve efficacy and therapeutic applicability of PROTACs. Read more
Automated customized antibody purification with flowbot ONE
Automating small-scale purification, e.g., of antibodies, can enable more research, shorten workflows, free up time for other tasks, and standardize results. This application note by flow robotics demonstrates the development of an automated purification solution for human IgG samples (YUMAB) using the flowbot® ONE* and PhyTip® columns. Read more
YUMAB and MOLCURE Collaborate To Advance Zero-Shot AI Antibody Discovery Technology For Undrugged Targets
YUMAB and MOLCURE Collaborate To Advance Zero-Shot AI Antibody Discovery Technology For Undrugged Targets YUMAB GmbH (“YUMAB”), a leading antibody discovery CRO headquartered in Braunschweig, Germany, and MOLCURE Inc. (“MOLCURE”), an AI-driven drug discovery company based in Kawasaki, Japan, announced their on-going collaboration now includes advancing the application of zero-shot AI technology for antibody discovery. […]
BioCopy and YUMAB announce partnership for development of innovative safeTY-engager® platform
Accelerating the development of highly specific antibodies against pHLA targets to fight cancer. – The development of highly specific T cell engagers directed against pHLA tumor targets will be quick and easy. – BioCopy’s innovative pHLA screening technology characterizes drug candidates in great depth for their specific binding against the desired pHLA tumor target. – […]
